Paraoxonase 1 (PON1) polymorphisms and risk for essential tremor

被引：9

作者：

Garcia-Martin, E. ^{[1
]}

Martinez, C. ^{[2
]}

Alonso-Navarro, H. ^{[3
,4
]}

Benito-Leon, J. ^{[5
,6
]}

Puertas, I. ^{[3
]}

Rubio, L. ^{[3
]}

Lopez-Alburquerque, T. ^{[7
]}

Agundez, J. A. G. ^{[1
]}

Jimenez-Jimenez, F. J. ^{[3
,8
]}

机构：

[1] Univ Extremadura, Sch Biol Sci, Badajoz, Spain

[2] Univ Extremadura, Sch Med, Badajoz, Spain

[3] Univ Alcala, Hosp Principe de Asturias, Madrid, Spain

[4] Hosp La Mancha Ctr, Ciudad Real, Spain

[5] Hosp Mostoles, Madrid, Spain

[6] CIBERNED, Madrid, Spain

[7] Hosp Univ Salamanca, Salamanca, Spain

[8] Hosp Sureste, Madrid, Spain

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2010年 / 17卷 / 06期

关键词：

essential tremor; genetics; paraoxonase; 1; polymorphism; risk factors; NAT2; GENE;

D O I：

10.1111/j.1468-1331.2009.02914.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: The polymorphic enzyme human serum paraoxonase 1 (PON1), encoded by the gene PON1 (chromosome 7q21.3), plays a major role in the metabolism of organophosphorus compounds. We investigated the possible association between the PON1 genotype and allelic variants of the polymorphisms Leu55Met and Glu192Arg, and the risk for essential tremor (ET). Methods: We studied the frequency of the PON1 genotypes and allelic variants in 201 patients with ET and 220 healthy controls using a PCR-RLFP method. Results: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms Leu55Met and Gln192Arg did not differ significantly between patients with ET and controls. These polymorphisms were unrelated with the age of onset of ET. Conclusions: PON1 polymorphisms are not related with the risk for ET.

引用

页码：879 / 881

页数：3

共 50 条

[41] Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice
Rozenberg, O
Shih, DM
Aviram, M
[J]. ATHEROSCLEROSIS, 2005, 181 (01) : 9 - 18
[42] DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
Sanghera, DK
Aston, CE
Saha, N
Kamboh, MI
[J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (01) : 36 - 44
[43] Macrophage paraoxonase 1 (PON1) binding sites
Efrat, Michal
Aviram, Michael
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 376 (01) : 105 - 110
[44] Serum paraoxonase 1 (PON1) measurement: an update
Ceron, Jose J.
Tecles, Fernando
Tvarijonaviciute, Asta
[J]. BMC VETERINARY RESEARCH, 2014, 10
[45] Paraoxonase 1 (PON1) status and substrate hydrolysis
Richter, Rebecca J.
Jarvik, Gail P.
Furlong, Clement E.
[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 235 (01) : 1 - 9
[46] Paraoxonase 1 (PON1) status in risk assessment for organophosphate exposure and pharmacokinetics
Furlong, Clement E.
Richter, Rebecca J.
Cole, Toby B.
Jarvik, Gail P.
Li, Wan-Fen
Thummel, Kenneth E.
Rettie, Allan E.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[47] Homocysteine levels, paraoxonase 1 (PON1) activity, and cardiovascular risk - Reply
Nicholls, Stephen J.
Hazen, Stanley L.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (02): : 169 - 169
[48] Serum paraoxonase 1 (PON1) measurement: an update
Jose J Ceron
Fernando Tecles
Asta Tvarijonaviciute
[J]. BMC Veterinary Research, 10
[49] Paraoxonase 1 (PON1) is present in postprandial chylomicrons
Fuhrman, B
Volkova, N
Aviram, M
[J]. ATHEROSCLEROSIS, 2005, 180 (01) : 55 - 61
[50] Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip
Cherry, N
Mackness, M
Durrington, P
Povey, A
Dippnall, M
Smith, T
Mackness, B
[J]. LANCET, 2002, 359 (9308): : 763 - 764

← 1 2 3 4 5 →